Three-year follow-up from the phase I/IIa trial of rAAV.sFlt-1 subretinal injection is encouraging for gene therapy for exudative age-related macular degeneration.
Michelle Dalton, ELS
Advertisement
Articles by Michelle Dalton, ELS
Advertisement
Latest Updated Articles
- Gene therapy for wet AMD shows promising long-term results
Published: February 1st 2016 | Updated:
